Eli Lilly, the company behind the newly approved obesity medication called Foundayo (also known as orforglipron), has shared exciting new results from a large study in people with Type 2 diabetes and obesity or overweight. In this study, called the Achieve-4 trial, Foundayo was compared to a common diabetes medication called insulin glargine. The results showed that Foundayo worked just as well as insulin in managing diabetes and was better at lowering blood sugar levels. Additionally, people taking Foundayo lost more weight and kept it off for up to two years. Importantly, the drug also reduced the risk of major heart problems—such as heart attacks, strokes, or heart-related hospital stays—by 16% compared to insulin. There was also a lower overall risk of death in the group taking Foundayo. The study included over 2,700 adults from 15 countries and is the largest and longest trial of Foundayo in people with Type 2 diabetes so far. Lilly is now preparing to submit these results to the U.S. Food and Drug Administration (FDA) to seek approval for Foundayo as a treatment for Type 2 diabetes by the end of June. The FDA had previously approved Foundayo for obesity in early April but asked for more information about its safety, particularly regarding heart risks, liver health, digestion, and use in breastfeeding women. The Achieve-4 study provided some of this information, showing no signs of liver problems and confirming its heart safety benefits. Foundayo is part of a new class of medications called GLP-1 agonists, which help control blood sugar and support weight loss. Lilly is competing with another company, Novo Nordisk, which already has an oral weight-loss pill called Wegovy. Unlike Wegovy, which must be taken on an empty stomach in the morning with only a small amount of water, Foundayo can be taken at any time of day and does not require food or water restrictions. This convenience could give Foundayo an advantage in the market.